Biote (NASDAQ: BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners’ patients, today announced financial results for the ...

COLUMBUS, GA, UNITED STATES, March 3, 2026 /EINPresswire.com/ -- OBGYN Specialists of Columbus is helping women better ...

Christopher and Mary Pat Sharon are suing Biote Medical. They allege that a sleep supplement from the Irving-based company caused them both liver damage. Courtesy of Brewer, Attorneys & A former ...

As Biote navigates a period of operational realignment, investor attention is fixed on its ability to manage significant one-time expenses while sustaining its growth trajectory. The market awaits the ...

It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it happened in biote Corp.'s (NASDAQ:BTMD) case, it's fantastic news for shareholders.

The hormone-therapy supplier trades at bargain multiples and keeps strong margins, yet falling procedure volumes and negative cash flow still hang over the turnaround. Biote Corp (NASDAQ: BTMD) is a ...

Hormone pellet therapy provider BioTE filed a lawsuit against Gary S. Donovitz on Oct. 7 in Delaware Court of Chancery. The suit, brought by Richards Layton & Finger, seeks to halt the defendant's ...

Operator: Good day, and welcome to the Biote Second Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note that today’s event is being recorded. I would now like to turn the ...

Fintel reports that on August 7, 2025, B. Riley Securities downgraded their outlook for biote (NasdaqGM:BTMD) from Buy to Neutral. Analyst Price Forecast Suggests 76.12% Upside As of August 6, 2025, ...

The company adjusted its fiscal 2025 revenue guidance to be "above $190 million" and fiscal 2025 adjusted EBITDA guidance to be "above $50 million." Peterson stated, "For the full year, we forecast ...